Univariate analysis for patients with non-Hodgkin lymphoma: overall survival and progression-free survival rates
| Prognostic factors at time of transplantation . | Overall survival . | Progression-free survival . | ||||
|---|---|---|---|---|---|---|
| Relative risk . | 95% CI . | P . | Relative risk . | 95% CI . | P . | |
| Age ≥ 60 vs < 60 | 1.05 | .57-1.94 | .87 | .94 | .54-1.66 | .84 |
| ALC ≥ 500 cells/μL vs < 500 cells/μL | .07 | .03-.16 | < .0001 | .09 | .04-.18 | < .0001 |
| ANC ≥ 500 cells/μL vs < 500 cells/μL | .43 | .21-.88 | .02 | .49 | .25-.95 | .034 |
| Chemosensitive disease (CR + PR) | .39 | .095-1.62 | .2 | .73 | .26-2.02 | .55 |
| CR status before transplantation | .71 | .34-1.47 | .35 | .66 | .33-1.32 | .24 |
| Extranodal sites ≥ 2 vs < 2 | 2.66 | .95-7.48 | .06 | 2.14 | .77-5.958 | .14 |
| LDH level normal for age/sex vs > normal | .59 | .33-1.06 | .077 | .81 | .47-1.39 | .44 |
| Performance status ≥ 2 vs < 2 | 2.6 | 1.09-6.16 | .03 | 2.43 | 1.03-5.71 | .04 |
| No. pretransplant chemotherapy regimens | 1.11 | .78-1.58 | .57 | .96 | .67-1.37 | .82 |
| Stage III/IV | 1.59 | .8-3.1 | .17 | 1.2 | .68-2.15 | .53 |
| Stem cell source | ||||||
| BM vs PBSCs | .85 | .46-1.57 | .61 | .84 | .48-1.47 | .55 |
| Platelet level > 20 × 109/L vs ≤ 20 × 109/L | .67 | .35-1.26 | .21 | .89 | .48-1.63 | .70 |
| Prognostic factors at time of transplantation . | Overall survival . | Progression-free survival . | ||||
|---|---|---|---|---|---|---|
| Relative risk . | 95% CI . | P . | Relative risk . | 95% CI . | P . | |
| Age ≥ 60 vs < 60 | 1.05 | .57-1.94 | .87 | .94 | .54-1.66 | .84 |
| ALC ≥ 500 cells/μL vs < 500 cells/μL | .07 | .03-.16 | < .0001 | .09 | .04-.18 | < .0001 |
| ANC ≥ 500 cells/μL vs < 500 cells/μL | .43 | .21-.88 | .02 | .49 | .25-.95 | .034 |
| Chemosensitive disease (CR + PR) | .39 | .095-1.62 | .2 | .73 | .26-2.02 | .55 |
| CR status before transplantation | .71 | .34-1.47 | .35 | .66 | .33-1.32 | .24 |
| Extranodal sites ≥ 2 vs < 2 | 2.66 | .95-7.48 | .06 | 2.14 | .77-5.958 | .14 |
| LDH level normal for age/sex vs > normal | .59 | .33-1.06 | .077 | .81 | .47-1.39 | .44 |
| Performance status ≥ 2 vs < 2 | 2.6 | 1.09-6.16 | .03 | 2.43 | 1.03-5.71 | .04 |
| No. pretransplant chemotherapy regimens | 1.11 | .78-1.58 | .57 | .96 | .67-1.37 | .82 |
| Stage III/IV | 1.59 | .8-3.1 | .17 | 1.2 | .68-2.15 | .53 |
| Stem cell source | ||||||
| BM vs PBSCs | .85 | .46-1.57 | .61 | .84 | .48-1.47 | .55 |
| Platelet level > 20 × 109/L vs ≤ 20 × 109/L | .67 | .35-1.26 | .21 | .89 | .48-1.63 | .70 |